Spring Bank Pharmaceuticals Inc Expected to Earn Q4 2019 Earnings of ($0.51) Per Share (SBPH)

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) – Investment analysts at Jefferies Financial Group issued their Q4 2019 earnings estimates for Spring Bank Pharmaceuticals in a research note issued on Tuesday, March 12th. Jefferies Financial Group analyst M. Raycroft forecasts that the company will post earnings per share of ($0.51) for the quarter. Jefferies Financial Group also issued estimates for Spring Bank Pharmaceuticals’ FY2023 earnings at $5.69 EPS.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last announced its earnings results on Monday, March 11th. The company reported ($0.33) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.17.

Several other analysts have also recently commented on the company. Chardan Capital set a $45.00 target price on Spring Bank Pharmaceuticals and gave the company a “buy” rating in a report on Friday, November 30th. Cantor Fitzgerald set a $34.00 target price on Spring Bank Pharmaceuticals and gave the company a “buy” rating in a report on Friday, December 7th. Finally, Zacks Investment Research cut Spring Bank Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Spring Bank Pharmaceuticals presently has an average rating of “Buy” and an average target price of $33.00.

Shares of SBPH stock opened at $10.44 on Thursday. Spring Bank Pharmaceuticals has a one year low of $8.14 and a one year high of $15.73. The company has a market capitalization of $172.09 million, a P/E ratio of -5.58 and a beta of 0.80.

Several institutional investors have recently bought and sold shares of the business. Northern Trust Corp boosted its holdings in shares of Spring Bank Pharmaceuticals by 0.9% during the 4th quarter. Northern Trust Corp now owns 171,750 shares of the company’s stock worth $1,785,000 after buying an additional 1,507 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Spring Bank Pharmaceuticals by 5.9% during the 4th quarter. Bank of New York Mellon Corp now owns 43,789 shares of the company’s stock worth $454,000 after buying an additional 2,430 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Spring Bank Pharmaceuticals by 65.3% during the 4th quarter. Rhumbline Advisers now owns 16,771 shares of the company’s stock worth $174,000 after buying an additional 6,623 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Spring Bank Pharmaceuticals by 8.7% during the 4th quarter. Geode Capital Management LLC now owns 116,861 shares of the company’s stock worth $1,214,000 after buying an additional 9,398 shares in the last quarter. Finally, Blair William & Co. IL bought a new position in shares of Spring Bank Pharmaceuticals during the 3rd quarter worth approximately $123,000. Hedge funds and other institutional investors own 43.18% of the company’s stock.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).

Further Reading: Return on Investment (ROI)

Earnings History and Estimates for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit